Lifang Mb Huang

Lifang Mb Huang

Auto-generated profile, based on publicly available information

Lifang Mb Huang

Department of metabolic Endocrinology

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2021 in Medicine
Verified
Journal Article
Open access
LHLifang Mb Huang
Lifang Mb Huang
LWLang Mb Wang
Lang Mb Wang
JTJianghong Mb Tan
Jianghong Mb Tan
HLHong Mb Liu
Hong Mb Liu
YNYanhui Mb Ni
Yanhui Mb Ni
Background: Patients infected with a virus usually lack vitamin C. High-dose vitamin C has an antiviral effect, and has been used by several researchers to treat COVID-19 by intravenous infusion, achieving good results. However, the efficacy and safety of vitamin C in the treatment of patients with COVID-19 remain unclear. Thus, the aim of the present study was to investigate the efficacy of high-dose vitamin C infusion in the treatment of patients with COVID-19. Methods: Electronic databases were searched, including PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Web of Science, China National Knowledge Infrastructure database, Chinese Wanfang database, and Chinese Biomedical Literature database. The aim was to collect randomized controlled trials of high-dose vitamin C infusion in the treatment of patients with COVID-19, with the retrieval time being from the establishment of the database to March 2021. In accordance with the pre-designed inclusion/exclusion criteria, all data were extracted independently by 2 researchers. To assess the risk bias in the studies, the Cochrane collaboration's tool for assessing risk of bias was used to assess the risk bias in the studies, while meta-analysis was performed using Revman 5.3 software. Results: In the present study, a high-quality comprehensive evaluation is provided of high-dose vitamin C infusion in the treatment of patients with COVID-19. Conclusion: Further convincing evidence for the clinical treatment of COVID-19 is provided, in addition to evidence-based guidance for clinical practice. PROSPERO Registration Number: CRD42021246342.

10 March 2010 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
KZKun Zhou
Kun Zhou
LHLifang Huang
Lifang Huang
ZZZhi-Gang Zhou
Zhi-Gang Zhou
CHCaihong Hu
Caihong Hu
WLWenli Liu
Wenli Liu
HSHanying Sun
Hanying Sun